Luvadaxistat
Sponsors
Neurocrine Biosciences
Conditions
Schizophrenia
Phase 2
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
CompletedNCT03359785
Start: 2018-01-10End: 2020-12-21Updated: 2024-02-28
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
CompletedNCT03382639
Start: 2018-01-04End: 2021-01-12Updated: 2024-02-28
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
TerminatedNCT05182476
Start: 2021-12-07End: 2024-10-14Updated: 2025-07-02